NCT00282100View on ClinicalTrials.gov

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Liver Cancer
Interventions
DRUG

Gefetinib (Iressa)

Trial Locations (1)

308433

Tan Tock Seng Hospital, Singapore

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Singapore Cancer Syndicate.

UNKNOWN

collaborator

AstraZeneca

INDUSTRY

lead

Tan Tock Seng Hospital

OTHER

NCT00282100 - Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter